Helen K. Ellias serves as Executive at SAB Biotherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Helen K. Ellias has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Nov 24, 2023 involved exercising options for 2,857,142 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | SABS | $0 | Option Exercise | 2,857,142 | $N/A | Discretionary |
Helen K. Ellias currently holds 2,857,142 shares of SAB Biotherapeutics, Inc. (SABS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Helen K. Ellias has been a net neutral trader of SABS stock. They have purchased $0 and sold $0 worth of shares.
Helen K. Ellias's most recent insider trade was on Nov 24, 2023, when they sold 2,857,142 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted